Amgen is a U.S. biotechnology company focused on discovering, developing, manufacturing, and delivering innovative human therapeutics for serious illnesses. It is headquartered in Thousand Oaks, California and has operated as a biotechnology pioneer since 1980.
Recent biosimilar and biologic developments included Health Canada approval of denosumab biosimilars, FDA review actions, and new licensing and commercialisation agreements. Other updates covered court, trial and reimbursement agenda decisions.
Healthcare stocks were described as a defensive sector facing 2026 reimbursement headwinds, while capex rankings showed HCA Healthcare, Johnson & Johnson and Merck at the top. The sources also highlighted how capex differs across providers, device makers and drug developers.
Novartis is emphasizing innovative medicines across oncology, immunology, neuroscience and gene therapy. The company targets mid-single-digit sales growth through 2027 and core operating income margins above 35%.
President Trump imposes 100% tariffs on imported branded drugs from companies refusing price cuts or U.S. production moves. Sixteen major pharmaceutical firms have secured tariff exemptions by agreeing to align U.S. prices with other developed nations and invest in domestic manufacturing. The policy aims to reduce prescription drug costs and rebuild domestic pharmaceutical production capacity.
Market analysis reports project substantial growth through 2033 across sarcopenia treatments, oncology injection drugs, and ASO-based therapies. Major pharmaceutical companies including Pfizer, Merck, Roche, Novartis, and Amgen feature prominently across all three therapeutic areas. The reports cover market segmentation, geographic analysis, and competitive landscapes for each sector.
Pharmaceutical companies are delaying European drug launches due to uncertainty over U.S. pricing policies under President Trump. New drug launches in EU markets fell 35% following Trump's executive order on international reference pricing. Companies fear lower European prices could undermine their ability to maintain higher prices in the $700 billion U.S. market.
Over 25 companies are developing 30+ therapies for celiac disease, with recent positive trial results and FDA Fast Track designation. A new blood test using T-cell receptor sequencing may enable noninvasive diagnosis and monitoring.
The FDA is expected to issue draft guidance reducing testing requirements for biosimilar drugs, potentially lowering development costs by USD 20 million. The move comes as the biosimilars market shows strong growth, with major launches in 2025.
Amgen shares have climbed 35% over six months, trading near $388, as analysts raise price targets following strong fourth-quarter 2025 results and expanding oncology pipeline programs including IMDELLTRA and LUMAKRAS.
Genmab is moving GEN1106, a SLITRK6-targeting ADC acquired through its $1.8bn ProfoundBio takeover, into phase 1 trials despite several recent discontinuations and the 2017 failure of the only other similar project.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07598825 |
A Trial of Inebilizumab in Participants With Autoimmune Hepatitis |
NOT_YET_RECRUITING | PHASE3 |
| NCT07590193 |
A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus |
NOT_YET_RECRUITING | PHASE1 |
| NCT07575399 |
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07545226 |
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose. |
NOT_YET_RECRUITING | PHASE1 |
| NCT07531095 |
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) |
RECRUITING | PHASE1 |
| NCT07526298 |
Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Activity in Apparently Stable Patients |
NOT_YET_RECRUITING | |
| NCT07523711 |
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity |
RECRUITING | PHASE1 |
| NCT07493512 |
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer |
RECRUITING | PHASE1 |
| NCT07478887 |
Impact of the Corrie Lipids Digital Health Program on Lipid Optimization |
RECRUITING | NA |
| NCT07444190 |
Psychological Burden of Thyroid Eye Disease |
COMPLETED |
